AxoGen, Inc. (AXGN)

NASDAQ • Healthcare

$45.44

+$0.46 (+1.0%)

Market closed

Last close at September 16, 2026 at 20:00 UTC

Open$44.87

Day Range$44.15 - $46.35

Avg. Volume (3M)1.2M

Market Cap$2.4B

52 Week Range

$15.27$52.91

Next EarningsIn 49 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$69.7M100%

Gross Profitminus cost of goods$50.6M73%

In plain terms: out of every $100 in revenue, AxoGen, Inc. currently loses $2.

Fundamentals & Financials

Revenue (TTM)

$251.1M

Net Income (TTM)

-$33.5M

EPS (TTM)

-$0.67

ROA (TTM)

-11%

Current Ratio

6.6

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+100.0%Q3 2025$0.12

+33.3%Q4 2025$0.12

-21.2%Q1 2026$0.07

-41.7%Q2 2026$0.07

-1.2%Q3 2026$0.12

Nov 4

in 49 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -1.2%

AxoGen, Inc. topped consensus in the second fiscal quarter of 2026, reporting revenue of $69.7 million against a $67.1 million estimate, +3.9%, when it reported results on July 29, 2026. Revenue rose 23.1% from $56.7 million a year ago, with the U.S. market carrying nearly all of the quarter at about $69.0 million. Gross profit came to about $50.7 million, with gross margin near 73%, while operating margin was about -3% as operating income came in at about -$2.2 million. Adjusted EPS was $0.12, up 0.0% from a year ago, and the company posted a net loss of about $1.5 million versus net income of about $579,000 a year ago. Operating cash flow was about $1.5 million. Consensus for the next period calls for EPS of $0.14 on revenue of $73.2 million.

View full earnings history

About AxoGen, Inc.

AxoGen, Inc. develops and sells healthcare products for repairing injured or severed peripheral nerves and trades on the NASDAQ under AXGN. In FY2025, the company generated $225.2 million in revenue from a portfolio of surgical nerve repair and soft-tissue products used by clinicians in reconstructive procedures.

Name

AxoGen, Inc.

CEO

Michael D. Dale

Website

www.axogeninc.com

Industry

Healthcare

Employees

622

Today's Snapshot

AI-generated

AXGN closed 1.1% above yesterday's close, while its sector was flat.

Trading Volume

Below 10d avg (1.5M)

1.4M

vs S&P 500 Today

Outperforming Market

+1.63%

Updated: September 16, 2026 at 20:15 UTC

Technical Indicators

2 Buy2 Neutral4 Sell

AXGN carries a sell tilt as short-term momentum and MACD readings turn negative while the broader 200-day averages remain well below current levels, highlighting a longer-term uptrend that contrasts with nearer-term weakness. Trend strength is moderate and not strongly directional, and volatility is elevated with a notable ATR, which amplifies downside moves. On-balance volume shows accumulation, creating a mixed picture, but short-term momentum loss and negative MACD weigh on near-term bias; the pivot sits slightly below price. Technical takeaway: sell bias rooted in weakening short-term momentum despite longer-term support.

All signals